ADUS Quote, Financials, Valuation and Earnings

Chemed has a net margin of 6.29% compared to Addus HomeCare's net margin of 11.09%. Addus HomeCare's return on equity of 8.66% beat Chemed's return on equity of 26.04%.

Addus HomeCare has a consensus price target of $136.10, signalling upside risk potential of 17.7%. On the other hand Chemed has an analysts' consensus of $677.33 which suggests that it could grow by 16.54%. Given that Addus HomeCare has higher upside potential than Chemed, analysts believe Addus HomeCare is more attractive than Chemed.

Addus HomeCare has a beta of 0.850, which suggesting that the stock is 14.958% less volatile than S&P 500. In comparison Chemed has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.659%.

Addus HomeCare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Chemed offers a yield of 0.33% to investors and pays a quarterly dividend of $0.50 per share. Addus HomeCare pays -- of its earnings as a dividend. Chemed pays out 8.97% of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Addus HomeCare quarterly revenues are $337.7M, which are smaller than Chemed quarterly revenues of $646.9M. Addus HomeCare's net income of $21.2M is lower than Chemed's net income of $71.8M. Notably, Addus HomeCare's price-to-earnings ratio is 26.10x while Chemed's PE ratio is 28.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Addus HomeCare is 1.70x versus 3.51x for Chemed. Usually stocks with elevated PS ratios are considered overvalued.

Health Catalyst has a net margin of 6.29% compared to Addus HomeCare's net margin of -29.9%. Addus HomeCare's return on equity of 8.66% beat Health Catalyst's return on equity of -20.06%.

Addus HomeCare has a consensus price target of $136.10, signalling upside risk potential of 17.7%. On the other hand Health Catalyst has an analysts' consensus of $8.09 which suggests that it could grow by 114.05%. Given that Health Catalyst has higher upside potential than Addus HomeCare, analysts believe Health Catalyst is more attractive than Addus HomeCare.

Addus HomeCare has a beta of 0.850, which suggesting that the stock is 14.958% less volatile than S&P 500. In comparison Health Catalyst has a beta of 1.559, suggesting its more volatile than the S&P 500 by 55.873%.

Addus HomeCare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Health Catalyst offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Addus HomeCare pays -- of its earnings as a dividend. Health Catalyst pays out -- of its earnings as a dividend.

Addus HomeCare quarterly revenues are $337.7M, which are larger than Health Catalyst quarterly revenues of $79.4M. Addus HomeCare's net income of $21.2M is higher than Health Catalyst's net income of -$23.7M. Notably, Addus HomeCare's price-to-earnings ratio is 26.10x while Health Catalyst's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Addus HomeCare is 1.70x versus 0.76x for Health Catalyst. Usually stocks with elevated PS ratios are considered overvalued.

Option Care Health has a net margin of 6.29% compared to Addus HomeCare's net margin of 3.51%. Addus HomeCare's return on equity of 8.66% beat Option Care Health's return on equity of 15.22%.

Addus HomeCare has a consensus price target of $136.10, signalling upside risk potential of 17.7%. On the other hand Option Care Health has an analysts' consensus of $38.56 which suggests that it could grow by 20.04%. Given that Option Care Health has higher upside potential than Addus HomeCare, analysts believe Option Care Health is more attractive than Addus HomeCare.

Addus HomeCare has a beta of 0.850, which suggesting that the stock is 14.958% less volatile than S&P 500. In comparison Option Care Health has a beta of 0.763, suggesting its less volatile than the S&P 500 by 23.686%.

Addus HomeCare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Addus HomeCare pays -- of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend.

Addus HomeCare quarterly revenues are $337.7M, which are smaller than Option Care Health quarterly revenues of $1.3B. Addus HomeCare's net income of $21.2M is lower than Option Care Health's net income of $46.7M. Notably, Addus HomeCare's price-to-earnings ratio is 26.10x while Option Care Health's PE ratio is 25.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Addus HomeCare is 1.70x versus 1.06x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

OptimizeRx has a net margin of 6.29% compared to Addus HomeCare's net margin of -10.03%. Addus HomeCare's return on equity of 8.66% beat OptimizeRx's return on equity of -13.03%.

Addus HomeCare has a consensus price target of $136.10, signalling upside risk potential of 17.7%. On the other hand OptimizeRx has an analysts' consensus of $15.08 which suggests that it could grow by 19.33%. Given that OptimizeRx has higher upside potential than Addus HomeCare, analysts believe OptimizeRx is more attractive than Addus HomeCare.

Addus HomeCare has a beta of 0.850, which suggesting that the stock is 14.958% less volatile than S&P 500. In comparison OptimizeRx has a beta of 1.283, suggesting its more volatile than the S&P 500 by 28.349%.

Addus HomeCare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OptimizeRx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Addus HomeCare pays -- of its earnings as a dividend. OptimizeRx pays out -- of its earnings as a dividend.

Addus HomeCare quarterly revenues are $337.7M, which are larger than OptimizeRx quarterly revenues of $21.9M. Addus HomeCare's net income of $21.2M is higher than OptimizeRx's net income of -$2.2M. Notably, Addus HomeCare's price-to-earnings ratio is 26.10x while OptimizeRx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Addus HomeCare is 1.70x versus 2.46x for OptimizeRx. Usually stocks with elevated PS ratios are considered overvalued.